Sun Pharma gets USFDA filing acceptance of new drug application for Deuruxolitinib
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
WINLEVI works differently from any other topical acne treatment
The companies will work with investigators to share the results with the scientific community
Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
        Subscribe To Our Newsletter & Stay Updated